<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03934450</url>
  </required_header>
  <id_info>
    <org_study_id>PQ Study 2</org_study_id>
    <nct_id>NCT03934450</nct_id>
  </id_info>
  <brief_title>Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen</brief_title>
  <official_title>Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi, Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi, Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the comparative tolerability, metabolism and pharmacokinetics of individual
      enantiomers of PQ in healthy human volunteers, receiving study drug over the course of 7
      days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this project is to investigate the comparative tolerability,
      metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers.
      Based on the results of this study, if one enantiomer seems to show a better safety profile
      (in terms of hematological effects), an analogous study will be carried out in G6PD deficient
      individuals (under a separate protocol). The studies are primarily aimed at understanding the
      tolerability and safety of the enantiomers in G6PD deficiency. If one shows a better safety
      profile, ultimately the evaluation of its efficacy will be required.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2018</start_date>
  <completion_date type="Actual">May 1, 2019</completion_date>
  <primary_completion_date type="Actual">May 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This study is a single center, prospective, cross-over phase 1 trial. Thirty-six participants will be enrolled into a two Cohort pharmacokinetic study evaluating the metabolism, pharmacokinetic behavior and tolerability of two dose levels (low/high) of primaquine enantiomers (and placebo) over the course of 7 days.
Placebo will be added in order to assess tolerability of enantiomers. Placebo control is needed in non-drug related clinical responses.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will not be able to know the sequence of the drug adminstration</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Methemoglobin concentration in blood from baseline</measure>
    <time_frame>Days 0, 3, 5, 7</time_frame>
    <description>Change in Methemoglobin concentration in blood from baseline (% hemoglobin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primaquine Plasma concentration, ng/mL</measure>
    <time_frame>Days 0, 3, 5, 7</time_frame>
    <description>Plasma concentrations of parent drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carboxy- Primaquine Plasma concentration, ng/mL</measure>
    <time_frame>Days 0, 3, 5, 7</time_frame>
    <description>Plasma concentrations of carboxy-primaquine metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primaquine N-carbamoyl-glucuronide Plasma concentration, ng/mL</measure>
    <time_frame>Days 0, 3, 5, 7</time_frame>
    <description>Plasma concentrations of Primaquine N-carbamoyl-glucuronide metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primaquine Orthoquinone Plasma concentration, ng/mL</measure>
    <time_frame>Days 0, 3, 5, 7</time_frame>
    <description>Plasma concentrations of Primaquine Orthoquinone metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hematocrit (%) Compared to baseline</measure>
    <time_frame>Days 0, 3, 5, 7</time_frame>
    <description>Change in Hematocrit (%) Compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin (g/dL) Compared to baseline</measure>
    <time_frame>Days 0, 3, 5, 7</time_frame>
    <description>Change in Hemoglobin (g/dL) Compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AST (U/L) Compared to baseline</measure>
    <time_frame>Days 0, 3, 5, 7</time_frame>
    <description>Change in Aspartate aminotransferase (U/L) Compared to baseline; used to monitor liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ALT (U/L) Compared to baseline</measure>
    <time_frame>Days 0, 3, 5, 7</time_frame>
    <description>Change in Alanine aminotransferase (U/L) Compared to baseline; used to monitor liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Bilirubin (mg/dL) Compared to baseline</measure>
    <time_frame>Days 0, 3, 5, 7</time_frame>
    <description>Change in Total Bilirubin (mg/dL) Compared to baseline; used to monitor liver function and red cell integrity</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Malaria</condition>
  <condition>Glucose 6 Phosphate Dehydrogenase Deficiency</condition>
  <arm_group>
    <arm_group_label>RPQ (-) enantiomer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 will receive 15 mg of RPQ (3A) every day for 7 days Cohort 2 will receive 22.5 mg of RPQ (3A) every day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPQ (+) enantiomer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 will receive 15 mg of SPQ (2A) every day for 7 days Cohort 2 will receive 22.5 mg of SPQ (2A) every day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primaquine Phosphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cohort 1 will receive 30 mg of RSPQ (1A) every day for 7 days Cohort 2 will receive 45 mg of RSPQ (1A) every day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 1 will receive placebo (4A) capsules everyday for seven days Cohort 2 will receive placebo (4A) capsules everyday for seven days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPQ</intervention_name>
    <description>The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.</description>
    <arm_group_label>RPQ (-) enantiomer</arm_group_label>
    <other_name>R-(-) Enantiomer of Primaquine Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPQ</intervention_name>
    <description>The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.</description>
    <arm_group_label>SPQ (+) enantiomer</arm_group_label>
    <other_name>S-(+) Enantiomer of Primaquine Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine Phosphate</intervention_name>
    <description>The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.</description>
    <arm_group_label>Primaquine Phosphate</arm_group_label>
    <other_name>Racemic Primaquine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal, healthy adults aged 18 to 65 years

        Exclusion Criteria:

          -  Known history of liver, kidney or hematological disease

          -  Known history of cardiac disease, Non Sinus Rhythm arrhythmia or QT prolongation

          -  Autoimmune disorders

          -  Report of an active infection

          -  Evidence of G6PD deficiency

          -  Participant is pregnant or breast-feeding, or is expecting to conceive during the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Walker, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Mississippi</name>
      <address>
        <city>University</city>
        <state>Mississippi</state>
        <zip>38677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemolysis</keyword>
  <keyword>Primaquine</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucosephosphate Dehydrogenase Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primaquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

